Corvus Pharmaceuticals Inc (NASDAQ:CRVS) – Research analysts at Cantor Fitzgerald lifted their FY2017 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst M. Goldstein now forecasts that the company will earn ($3.35) per share for the year, up from their prior estimate of ($3.64). Cantor Fitzgerald has a “Buy” rating and a $25.00 price target on the stock.
Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Friday, March 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.03.
COPYRIGHT VIOLATION NOTICE: “Corvus Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($3.35) Per Share (CRVS)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/04/21/fy2017-earnings-estimate-for-corvus-pharmaceuticals-inc-crvs-issued-by-cantor-fitzgerald-updated-updated.html.
CRVS has been the subject of several other reports. Zacks Investment Research lowered Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 21st. Cowen and Company reaffirmed an “outperform” rating on shares of Corvus Pharmaceuticals in a report on Thursday, April 6th. Finally, Credit Suisse Group AG reduced their target price on Corvus Pharmaceuticals from $26.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, April 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.67.
Corvus Pharmaceuticals (NASDAQ:CRVS) traded up 1.55% on Thursday, hitting $9.80. The company had a trading volume of 237,956 shares. The stock’s 50-day moving average price is $15.75 and its 200 day moving average price is $14.99. The company’s market capitalization is $205.14 million. Corvus Pharmaceuticals has a one year low of $8.27 and a one year high of $22.14.
Institutional investors have recently bought and sold shares of the stock. Ladenburg Thalmann Financial Services Inc. increased its position in Corvus Pharmaceuticals by 62.4% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 15,350 shares of the company’s stock valued at $220,000 after buying an additional 5,900 shares during the last quarter. TD Asset Management Inc. purchased a new position in Corvus Pharmaceuticals during the third quarter valued at approximately $387,000. Russell Investments Group Ltd. purchased a new position in Corvus Pharmaceuticals during the fourth quarter valued at approximately $402,000. Finally, FMR LLC increased its position in Corvus Pharmaceuticals by 123.6% in the fourth quarter. FMR LLC now owns 2,302,497 shares of the company’s stock valued at $32,926,000 after buying an additional 1,272,697 shares during the last quarter. Institutional investors and hedge funds own 78.00% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.